ESPR

ESPERION THERAPEUTICS INC NE

ESPR·29664W105·US·Common Stock·Healthcare - Drug Manufacturers - Specialty & Generic-13D/G

ESPR (ESPERION THERAPEUTICS INC NE) is held by 108 institutional investors as of Q1 2026. Largest holders: BlackRock, Inc. ($48.9M), WASATCH ADVISORS LP ($43.2M), VANGUARD CAPITAL MANAGEMENT LLC ($28.6M). Net institutional sentiment: Mixed.

108
Holders
Avg rating(29 Elite)
$344.1M
Total Value
54% (119)
Fund Consensus
62 buying - 52 selling
ESPRSmart Money Verdict
View all
Held by 108 funds
29 elite
Who's Trading
InsiderKLKoenig Sheldon L.Sell $169KJun 17, 2026
InsiderHBHalladay BenjaminSell $34KJun 17, 2026
InsiderLBLooker BenjaminSell $37KJun 17, 2026
ActivistGLGlazer Capital, LLC8.2%Jun 8, 2026
ActivistWasatch Advisors LPWasatch Advisors LP6.1%Apr 22, 2026
ActivistThe Vanguard GroupThe Vanguard Group0.0%Mar 26, 2026
InsiderKLKoenig Sheldon L.Sell $70KMar 17, 2026
InsiderHBHalladay BenjaminSell $17KMar 17, 2026
InsiderLBLooker BenjaminSell $15KMar 17, 2026
InsiderLBLooker BenjaminSell $5KJan 20, 2026
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
17.9M(+1.0%)$48.9M0.0%+33.47%
29
Increased
15.8M(+66.9%)$43.2M0.3%-24.21%
51
New
10.4M$28.6M0.0%+9.28%
40
Increased
9.5M(+99.5%)$25.9M0.0%-1.59%
46
Increased
7.1M(+29.3%)$19.4M0.0%+18.87%
36
Increased
7.1M(+19.0%)$19.3M0.0%+17.62%
33
Decreased
6.5M(-5.3%)$17.9M0.0%-13.07%
0
Increased
6M(+3.8%)$16.3M0.0%-23.65%
29
Increased
4.3M(+1269.6%)$11.8M0.0%+13.20%
45
Increased
3.6M(+0.0%)$9.9M0.0%+26.67%
28
New
3.5M$9.7M0.0%+9.28%
38
Decreased
2.7M(-22.2%)$7.5M0.0%+26.56%
0
Decreased
2.6M(-27.1%)$7.2M0.1%+5.25%
0
Decreased
2.4M(-15.4%)$6.6M0.0%+8.81%
0
Increased
2.1M(+2.0%)$5.9M0.0%-13.43%
28
Increased
2.1M(+5.4%)$5.8M0.0%-4.71%
29
New
1.7M$4.6M0.0%+9.28%
37
Decreased
1.6M(-26.2%)$4.4M0.0%+2.58%
0
New
1.6M$4.3M0.0%+9.28%
37
Increased
1.3M(+193.7%)$3.6M0.0%+11.12%
43

Showing 1-20 of 119

1 / 6

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used